ストックスクリーナーアプリを入手
4.52
0.78%
0.035
プレマーケット:
4.39
-0.13
-2.88%
前日終値:
$4.485
開ける：
$4.18
24時間の取引高:
159.37K
Relative Volume:
0.06
時価総額：
$4.66M
収益：
$212.10K
当期純損益:
$-40.19M
株価収益率:
-0.000851
EPS:
-5313.2836
ネットキャッシュフロー:
$-13.92M
1週間 パフォーマンス:
-35.06%
1か月 パフォーマンス:
-70.70%
6か月 パフォーマンス:
-99.59%
1年 パフォーマンス:
-99.99%
1日の値動き範囲:
$4.17
$4.91
1週間の範囲:
$4.17
$7.6928
52週間の値動き範囲:
$4.11
$54,500.00
Aditxt Inc Stock (ADTX) Company Profile
ADTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ADTX
Aditxt Inc
|
4.52 | 4.66M | 212.10K | -40.19M | -13.92M | -5,313.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.74 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
617.00 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
567.09 | 34.59B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.76 | 33.10B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
271.04 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Aditxt Inc (ADTX) 最新ニュース
Aditxt, Inc. SEC 10-K Report - TradingView
Aditxt, Inc. Updates on Pearsanta’s Strategic Acquisition - TipRanks
BioMedNewsBreaks — Evofem Biosciences Inc. (EVFM) Releases Second-Quarter 2024 Financial Results, Company Update - MSN
Upcoming Aditxt Weekly Update to Highlight Pearsanta's Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection - Quantisnow
Upcoming Aditxt Weekly Update to Highlight Pearsanta’s Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection - Business Wire
Aditxt, Inc. extends merger agreement with Evofem Biosciences By Investing.com - Investing.com Australia
Aditxt, Inc. extends merger agreement with Evofem Biosciences - Investing.com India
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Evofem Reports Fourth Consecutive Year of Net Sales Growth - Quantisnow
Aditxt, Inc. Highlights Strategic Partnership with Evofem - TipRanks
Evofem Posts Record 4th Year Growth: Revenue Up 6% as Operating Costs Plunge 27% - Stock Titan
Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk - Business Wire
SEC Form 10-K filed by Evofem Biosciences Inc. - Quantisnow
Evofem Biosciences Inc. (EVFM) reports earnings - Quartz
Small Cap Stocks To Follow TodayMarch 19th - MarketBeat
Top Small Cap Stocks To ResearchMarch 18th - MarketBeat
Aditxt Provides Business Status Overview and Announces Launch of Aditxt Weekly Update Starting Friday, March 21, 2025 - Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Aditxt Subsidiary Pearsanta Engages Dominari Securities for its Initial Public Offering, to Drive U.S. and Global Commercial Launch of Early Cancer Detection and Diagnosis Targeted for H2 2025 - Marketscreener.com
Aditxt Shares Up After Acquisition Target Appili Files Funding Plans - MarketScreener
Top Midday Gainers -March 18, 2025 at 02:10 pm EDT - MarketScreener
S&P 500 Down 1%; Sarepta Therapeutics Shares Plunge - Benzinga
Why Aditxt (ADTX) Stock Is Skyrocketing - Benzinga
Aditxt more than doubles after Appili takeover deadline extended - TradingView
Dow Dips Over 200 Points; US Industrial Production Increases More than Expected - Benzinga
Appili Therapeutics expects Aditxt transaction to close in Q1 - TipRanks
Appili Therapeutics Announces Submission of U.S. Federal Government Funding Proposals and Provides Corporate and Aditxt Transaction Update - Lelezard
Appili Therapeutics Announces Submission Of US Federal Government Funding Proposals And Provides Corporate And Aditxt Transaction Update - Marketscreener.com
Aditxt advances on drug trials and acquisition strategies By Investing.com - Investing.com Australia
Dow Jumps 400 Points; US Retail Sales Increase Less Than Expected - Benzinga
Aditxt advances on drug trials and acquisition strategies - Investing.com India
Aditxt Reveals Ambitious Roadmap: Multiple Clinical Trials and 2025 Product Launch - StockTitan
Upcoming Stock Splits This Week (March 17 to March 21) – Stay Invested - The Globe and Mail
Aditxt announces 1-for-250 reverse stock split effective March 17 - MSN
Aditxt shares fall on 1-for-250 reverse stock split - MSN
ADTX stock plunges to 52-week low, touches $0.04 - Investing.com India
Crude Oil Falls 1%; Dollar General Posts Upbeat Sales - Benzinga
Nasdaq Down Over 100 Points; US Producer Inflation Stalls In February - Benzinga
ADTX stock plunges to 52-week low, touches $0.04 By Investing.com - Investing.com Australia
US Stocks Likely To Open Lower After A Brief Respite: 'Add Exposure To Equities' Amid Pullback, Says Expert - Benzinga
Why Intel Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket - Benzinga
Aditxt announces 1-for-250 reverse stock split By Investing.com - Investing.com Australia
Aditxt announces 1-for-250 reverse stock split - Investing.com
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Aditxt, Inc. Announces Reverse Stock Split Plan - TipRanks
Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-250 Reverse Stock Split Effective at the Open of Trading on March 17, 2025 - Business Wire
Aditxt Inc (ADTX) 財務データ
収益
当期純利益
現金流量
EPS
Aditxt Inc (ADTX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| HRT FINANCIAL LP | 10% Owner |
Oct 16 '24 |
Sale |
1.17 |
25,534 |
29,875 |
0 |
3.89%
0.13%
大文字化:
|
ボリューム (24 時間):